Vcanbio Cell & Gene Engineering Corp., Ltd. (600645.SH): The company has completed the repurchase of 2.58% of its shares at a total cost of 0.2 billion yuan.
On August 1st, Gelunhui reported that Vcanbio Cell & Gene Engineering (600645.SH) announced that on July 31, 2024, the company completed a buyback and had actually repurchased 12,052,740 shares of the company, accounting for 2.58% of the total share capital, with a maximum repurchase price of 21.15 yuan/share, a minimum repurchase price of 15.11 yuan/share, an average repurchase price of 16.59 yuan/share, and a total fund amount of 0.2 billion yuan.
Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Share Price Could Signal Some Risk
vcanbio cell & gene engineering corp.,ltd. (600645.SH) has cumulatively repurchased 2.14% of its shares, costing 168 million yuan.
VCANBIO Cell & Gene Engineering Corp., Ltd. (600645.SH) announced that as of June 30, 2024, the company has repurchased a cumulative total of 10,028,800 shares, accounting for 2.14% of the company's total share capital. The highest purchase price was 21.15 yuan/share and the lowest purchase price was 15.11 yuan/share. The total amount paid was 168 million yuan (excluding transaction fees).
vcanbio cell & gene engineering corp.,ltd. (600645.SH): Cumulative expenditure of 161 million yuan repurchased 2.06% of the shares.
As of June 26, 2024, vcanbio Cell & Gene Engineering Corp., Ltd. (600645.SH) announced that it has repurchased a cumulative total of 9,618,840 shares of the company through centralized bidding trading, accounting for 2.06% of the total share capital of the company. Compared with the last disclosure, it has increased by 0.14%. The highest purchase price was 21.15 yuan/share and the lowest was 15.11 yuan/share. The total amount paid was 161,070,220.30 yuan (excluding transaction commission and other fees).
Is Vcanbio Cell & Gene Engineering (SHSE:600645) Using Too Much Debt?
vcanbio cell & gene engineering corp.,ltd. (600645.SH): Received notice of acceptance for clinical trial application of pharmaceutical VUM02 injection.
On June 20th, Gelunhui reported that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., has recently obtained the "Notice of Acceptance" for the clinical trial application of the new indication for VUM02 injection (human umbilical cord-derived mesenchymal stem cell injection) issued by the Drug Evaluation Center (CDE) of the National Medical Products Administration. VUM02 injection, a frozen stem cell preparation independently developed by our company, is a new drug of umbilical cord-derived mesenchymal stem cells (UC-MSC) prepared by screening healthy newborn umbilical cord tissue, separating, amplifying, harvesting, and freezing. Clinical
Zhongyuan Xiehe (600645.SH) has repurchased a total of 8.983 million shares at a cost of 151 million yuan
Zhongyuan Xiehe (600645.SH) issued an announcement. As of May 31, 2024, the company has made a total number of repurchases...
Do Its Financials Have Any Role To Play In Driving Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Stock Up Recently?
Zhongyuan Kyowa (600645.SH): Storage business includes neonatal cord blood hematopoietic stem cells, etc.
Gelonghui, May 14, 丨 Zhongyuan Xiehe (600645.SH) said on the investor interactive platform that the company's storage business includes neonatal umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental subpluripotent stem cells, and adult immune cells, adipose mesenchymal stem cells, and dental pulp mesenchymal stem cells. In terms of cell therapy research and development, the company's current VUM02 injection derived from umbilical cord mesenchymal stem cells has been approved for IND. Ind. indications include decompensated liver cirrhosis, idiopathic pulmonary fibrosis, slow-acute (subacute) liver failure, acute respiratory distress syndrome, and grade II to IV acute when hormone therapy fails
Zhongyuan Kyowa (600645.SH): The concept of synthetic biology is quite broad. Currently, the company focuses on the development of stem cell drugs
Gelonghui, May 8, 丨 Zhongyuan Xiehe (600645.SH) said on the investor interactive platform that the company's main business includes preparation and storage of cell tests in the field of “precision prevention”; research, production and marketing of in vitro diagnostic raw materials, in vitro diagnostic reagents and devices in the field of “accurate diagnosis”; research and development of clinical applications of stem cells and immune cells in the “cell therapy” field; forming a “precision medicine” industry chain. The concept of synthetic biology is quite broad. Currently, the company focuses on the research and development of stem cell drugs.
Zhongyuan Xiehe (600645.SH): A total of 1.65% of the company's shares have been repurchased
Gelonghui, May 6, 丨 Zhongyuan Xiehe (600645.SH) announced that as of April 30, 2024, the company had repurchased a total of 7,707,940 shares, accounting for 1.65% of the company's total share capital. The highest purchase price was 17.95 yuan/share, the lowest price was 15.11 yuan/share, and the total amount paid was 125,389,095.38 yuan (not including transaction fees).
Zhongyuan Concord (600645.SH) released 2023 annual results, with net profit of 106 million yuan, a year-on-year decrease of 5.78%
Zhongyuan Concord (600645.SH) released its 2023 annual report. The company achieved operating income of 15 during the reporting period...
Zhongyuan Xiehe (600645.SH): A total of 4.7712 million shares have been repurchased
Gelonghui, April 14, 丨 Zhongyuan Xiehe (600645.SH) announced that as of April 12, 2024, the company had repurchased a total of 47712 million shares of the company through centralized bidding transactions, accounting for 1.02% of the company's total share capital, an increase of 0.28% compared with the previous disclosure. The highest purchase price was 17.50 yuan/share, the lowest price was 15.73 yuan/share, and the total amount paid was 78.21,500 yuan (not including transaction commissions and other fees).
Zhongyuan Concord (600645.SH): A total of 3.4699 million shares have been repurchased
Gelonghui, April 1, 丨 Zhongyuan Xiehe (600645.SH) announced that in order to protect the company's value and shareholders' rights, as of March 31, 2024, the company had repurchased 3.469,900 shares of the company's shares through centralized bidding transactions, accounting for 0.74% of the company's total share capital. The highest purchase price was 17.50 yuan/share, the lowest price was 15.73 yuan/share, and the total amount paid was 573.34 million yuan (excluding transaction fees and other fees).
The Five-year Loss for Vcanbio Cell & Gene Engineering (SHSE:600645) Shareholders Likely Driven by Its Shrinking Earnings
Zhongyuan Kyowa (600645.SH): VUM02 injection was used to treat the first case of idiopathic pulmonary fibrosis to complete group administration
Gelonghui March 14, 丨 Zhongyuan Xiehe (600645.SH) announced that its wholly-owned subsidiary Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration on April 4, 2023 for the treatment of idiopathic pulmonary fibrosis. The US Food and Drug Administration granted Wuhan Optics Valley Zhongyuan Pharmaceutical the qualification of umbilical cord-derived mesenchymal stem cells for use in idiopathic pulmonary fibrosis as an orphan drug. A wholly-owned subsidiary, Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd. independently developed a clinical trial of VUM02 injection for the treatment of idiopathic pulmonary fibrosis
Zhongyuan Concord (600645.SH): A total of 1,418,200 shares have been repurchased
Gelonghui, March 1, 丨 Zhongyuan Xiehe (600645.SH) announced that in order to protect the company's value and shareholders' rights, as of February 29, 2024, the company had repurchased 1,418,200 shares of the company's shares through centralized bidding transactions, accounting for 0.30% of the company's total share capital. The highest purchase price was 17.14 yuan/share, the lowest price was 15.73 yuan/share, and the total amount paid was 23,185,425 yuan (excluding transaction fees and other fees).
Zhongyuan Concord (600645.SH): Initial repurchase of 76,800 shares
Gelonghui, February 20, 丨 Zhongyuan Xiehe (600645.SH) announced that on February 20, 2024, in order to protect the company's value and shareholders' rights, the company bought back 76,800 shares for the first time through centralized bidding transactions, accounting for 0.0164% of the company's total share capital. The highest purchase price was 15.79 yuan/share, the lowest price was 15.73 yuan/share, and the total amount paid was 1,211,354 yuan.
Zhongyuan Xiehe (600645.SH): Plans to spend 100 million yuan to 200 million yuan to buy back shares
Gelonghui, Feb. 18: Zhongyuan Xiehe (600645.SH) announced that the company plans to buy back the company's shares through centralized bidding transactions through the Shanghai Stock Exchange stock trading system. On the one hand, it is intended to be used for corporate equity incentives, and on the other hand, it is necessary to protect the company's value and shareholders' rights. The total repurchase capital shall not be less than RMB 100 million (including the principal amount) and not more than RMB 200 million (including the principal amount), and the repurchase price shall not exceed RMB 22 per share (including the principal amount). It is proposed to use its own capital of 50 million yuan (including capital) to 10 million yuan (including capital) to repurchase the company's shares to implement equity incentives;
Declining Stock and Decent Financials: Is The Market Wrong About Vcanbio Cell & Gene Engineering Corp., Ltd (SHSE:600645)?
No Data